Document Detail

Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed.
MedLine Citation:
PMID:  16172549     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Relapse after an initial response to infliximab therapy poses a problem for maintenance treatment. AIM: To assess the effects of increasing the infliximab dosage in Crohn's disease (CD) patients who initially responded but flared during maintenance therapy. METHODS: This was an observational study. Twelve CD patients with both inflammatory and fistulizing manifestations were included. All patients initially responded to 5 mg/kg of infliximab, relapsed during maintenance therapy, and were treated with 10 mg/kg. The Harvey-Bradshaw index, the fistula activity, and steroid use were assessed before and after treatment with the increased dose of infliximab. RESULTS: The mean Harvey-Bradshaw index score after flare-up during treatment with 5 mg/kg of infliximab was 13.5+/-3.7. Treatment with 10 mg/kg, in a mean of 3.3 infusions, decreased the activity score to a mean of 8.8+/-2.5. Two patients were weaned off prednisone, and a reduced dose was possible in the other steroid-treated patients. CONCLUSIONS: Increasing the infliximab dose may be beneficial in CD patients who initially responded to therapy, but relapsed during maintenance with the lower dosage.
Yoram Menachem; Benjamin Avidan; Alexandra Lavy; Alon Lang; Eytan Bardan; Herma Fidder; Simon Bar-Meir; Yehuda Chowers
Related Documents :
20195879 - The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in taiw...
23471549 - Letrozole usage adjuvant to gonadotropins for ovulation induction for patients with clo...
20061299 - Rationale for leptin-replacement therapy for severe lipodystrophy.
20924159 - Cost-effectiveness of biological therapy in remission induction of moderate to severe p...
20532579 - Laryngeal involvement in behcet's disease-a challenge for treatment.
9145299 - Pathological evaluation of effect of anti-rheumatic drugs on type ii collagen-induced a...
3935869 - Lhrh-agonist treatment in clinical and experimental human breast cancer.
508549 - Gentamicin pharmacokinetics in kwashiorkor.
21251179 - Ly2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effe...
Publication Detail:
Type:  Journal Article     Date:  2005-09-16
Journal Detail:
Title:  Digestion     Volume:  72     ISSN:  0012-2823     ISO Abbreviation:  Digestion     Publication Date:  2005  
Date Detail:
Created Date:  2005-10-25     Completed Date:  2006-01-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0150472     Medline TA:  Digestion     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  124-8     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2005 S. Karger AG, Basel.
Department of Gastroenterology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage*
Crohn Disease / drug therapy*,  pathology
Gastrointestinal Agents / administration & dosage*
Middle Aged
Statistics, Nonparametric
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Gastrointestinal Agents; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Serum antibodies in first-degree relatives of patients with IBD: a marker of disease susceptibility?...
Next Document:  Edkins and a century of acid suppression.